Windlas Biotech Share Price

Windlas Biotech Limited operates in India’s pharmaceutical CDMO (Contract Development and Manufacturing Organisation) sector, providing a comprehensive range of services spanning product discovery, development, licensing, and commercial manufacturing of generic products including complex generics. It serves sixteen of the top twenty Indian pharmaceutical companies and employs over nine hundred professionals across four manufacturing facilities in Dehradun, Uttarakhand. Windlas Biotech share price has reflected growing investor interest in India’s organised domestic pharma CDMO sector.

Windlas Biotech Limited operates three distinct strategic business verticals – Generic Formulations CDMO, Trade Generics and Institutional, and Exports – with manufacturing capacity exceeding seven billion tablets and capsules annually. It commissioned Plant-V for injectable formulations in FY 2023-24 and the Plant-2 extension facility in FY 2024-25. Windlas Biotech share trend has remained sensitive to CDMO client additions, capacity utilisation, and export vertical growth. Windlas Biotech stock price live has served as a real-time indicator of India’s domestic pharmaceutical outsourcing sector confidence.

Windlas Biotech holds WHO-GMP (World Health Organization – Good Manufacturing Practice), US-FDA (United States Food and Drug Administration), and EU-GMP (European Union – Good Manufacturing Practice) certifications across its plants. Windlas Biotech share price 2025-2026 has demonstrated sensitivity to CDMO revenue growth and injectable capacity ramp-up. Windlas Biotech share price today continues to reflect post-peak consolidation following the FY 2024-25 correction. Windlas Biotech stock price has historically responded to quarterly revenue growth and export momentum signals.

Windlas Biotech Company Fundamentals

(A) Company Background

Windlas Biotech company history traces to its incorporation on February 19, 2001, as Windlas Biotech Private Limited in Dehradun, Uttarakhand. Windlas Biotech converted to a public limited company and listed on BSE Limited (BSE) and NSE (National Stock Exchange of India Limited) on August 16, 2021, under BSE code 543329 and NSE symbol WINDLAS. Windlas Biotech headquarters is at Golf Course Extension Road, Gurugram, Haryana, with manufacturing in Dehradun. Windlas Biotech expansion has progressed through commissioning of Plant-V (injectables, FY 2023-24) and the Plant-2 extension (FY 2024-25). Windlas Biotech share price has reflected this capacity-led growth journey since listing.

(B) Company Product Lines

Windlas Biotech product line spans three strategic verticals as of FY 2024-25.

Here is the updated overview of the Windlas Biotech business segments and Windlas Biotech key offerings, showcasing how the company adds value across the Windlas Biotech value chain for its diverse range of Windlas Biotech customers:

Contract Manufacturing (CMO) As a core part of the Windlas Biotech business segments, this service provides high-volume, third-party manufacturing for branded generics. It strengthens the Windlas Biotech value chain by offering Windlas Biotech customers access to WHO-GMP certified facilities for reliable, large-scale production.

Contract Research and Manufacturing Services (CRAMS) This is one of the premier Windlas Biotech key offerings, integrating formulation R&D with commercial production. It allows Windlas Biotech customers to outsource the entire lifecycle of a drug, from initial pilot batches to final market launch.

Customized Formulations This segment focuses on specialized delivery systems like pellet coating and nanosized crystals. By providing these advanced solutions, Windlas enhances the Windlas Biotech value chain, helping Windlas Biotech customers differentiate their products in competitive markets.

Regulatory Services A vital component of the Windlas Biotech key offerings, this service manages dossier preparation and global compliance. It reduces time-to-market for Windlas Biotech customers by navigating complex international regulatory landscapes.

Product Licensing Windlas offers a ready-to-use portfolio of generic formulations for immediate licensing. This allows Windlas Biotech customers to rapidly expand their product catalogs without the lead time typically required for independent research.

Trade Generics and OTC Brands This vertical represents one of the fastest-growing Windlas Biotech business segments, focusing on affordable medicine. It completes the Windlas Biotech value chain by reaching end-consumers directly through a robust distribution network in underserved regions.

(C) Company Revenue Model

Windlas Biotech generates revenue through CDMO service fees and product sales from its Generic Formulations vertical, branded product sales from Trade Generics, and export formulation supply – with CDMO constituting the dominant revenue contributor in FY 2024-25.

Windlas Biotech business model has remained asset-intensive with scalable contract manufacturing, where clients provide technical inputs and the company delivers finished products under stringent regulatory compliance. Windlas Biotech revenue streams have been anchored by long-term CDMO relationships with leading Indian pharma companies, supplemented by growing trade generics and export verticals. Windlas Biotech share price has reflected confidence in this multi-vertical CDMO-led revenue model. Windlas Biotech stock price has historically responded to CDMO volume growth and new client addition signals.

(D) Geographic Presence

Windlas Biotech geographic presence as of FY 2024-25:

Corporate Headquarters: Golf Course Extension Road, Gurugram, Haryana

India Footprint:

Manufacturing Plants 1, 2, 3, 4, 5, and 6: Selaqui and Dehradun, Uttarakhand

Sales and distribution: fourteen states across India

International Presence: Export of pharmaceutical formulations to regulated and semi-regulated markets across Asia, Africa, and Latin America

Windlas Biotech share price has remained responsive to Dehradun facility capacity utilisation and export order intake momentum.

(E) Leadership

Windlas Biotech leadership / Windlas Biotech board of directors as of FY 2024-25:

• Ashok Kumar Windlass – Whole Time Director
• Hitesh Windlass – Managing Director
• Manoj Kumar Windlass – Joint Managing Director
• Pawan Kumar Sharma – Executive Director
• Prachi Jain Windlass – Non-Executive Director
• Vivek Dhariwal – Independent Director (Chairman)
• Srinivasan Venkataraman – Independent Director
• Gaurav Gulati – Independent Director
• Komal Gupta – Chief Executive Officer & Chief Financial Officer
• Ananta Narayan Panda – Company Secretary

Windlas Biotech management reflects a promoter family-led structure with experienced independent directors. Windlas Biotech corporate governance aligns with SEBI (Securities and Exchange Board of India) LODR (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(F) Key Milestones

Windlas Biotech milestones from inception:

• 2001: Incorporated February 19, 2001, in Dehradun, Uttarakhand
• 2012-13: Commissioned Plant-3; expanded OSD (Oral Solid Dosage) manufacturing capacity
• 2019-20: Commissioned Plant-4; capacity expanded to over five billion tablets and capsules
• 2021: Listed on BSE and NSE on August 16, 2021; Windlas Biotech share price commenced public market journey at IPO (Initial Public Offering) price of ₹460 per share under BSE code 543329
• 2022: Capacity expanded to over seven billion tablets and capsules
• 2023-24: Commissioned Plant-5 for injectable formulations; Windlas Biotech share price has reflected injectable capacity diversification since this period
• 2024-25: Plant-2 extension facility commissioned; OSD capacity expansion at Plant-6 initiated

(G) Industry Perspective

India’s pharmaceutical CDMO industry has historically tracked outsourcing trends from large domestic branded generic manufacturers seeking to focus capital on marketing, distribution, and R&D while delegating manufacturing to compliant, scalable contract partners. Demand cycles have followed new drug launches, capacity constraints at innovator companies, and cost efficiency mandates across the Indian pharma sector.

As of FY 2024-25, India’s domestic CDMO sector is experiencing structural growth driven by increasing outsourcing adoption among top Indian pharmaceutical companies, the rapid expansion of the chronic therapeutic category (cardiovascular, anti-diabetic, CNS), and rising regulatory compliance requirements that favour larger, inspected CDMO operators over smaller, unregulated manufacturers. The injectable formulations CDMO sub-segment has emerged as the fastest-growing category, driven by domestic hospital channel demand and export market requirements. China-plus-one supply chain diversification strategies have further accelerated international pharma companies’ interest in Indian CDMOs. Windlas Biotech operates at the forefront of this structural industry shift. Windlas Biotech share price has reflected industry-level CDMO outsourcing momentum and injectable capacity expansion signals. Windlas Biotech stock price has remained responsive to sector-wide domestic pharma outsourcing trends through FY 2024-25.

Windlas Biotech Stock Market Presence – Listing And Index Representation

Windlas Biotech has been listed on BSE Limited (BSE) under scrip code 543329 and on NSE under symbol WINDLAS since August 16, 2021. The International Securities Identification Number (ISIN) is INE0H5O01029. Windlas Biotech share price has demonstrated small-cap to mid-cap liquidity characteristics, with a healthy mix of institutional and retail participation in daily traded volumes. It is classified under BSE SmallCap and BSE Allcap indices. Windlas Biotech stock price reflects a profile that underwent significant post-IPO correction before recovering strongly from FY 2023-24 through FY 2024-25. Windlas Biotech earnings have attracted growing analyst and institutional attention as CDMO revenue scale-up and injectable diversification have progressed through FY 2024-25.

Windlas Biotech Stock Performance And Share Price History

Windlas Biotech share price has traversed a notable multi-phase cycle since its August 2021 listing – an extended post-IPO correction phase through FY 2021-22 and FY 2022-23, followed by a sharp recovery and re-rating phase through FY 2023-24 and FY 2024-25. Over the one-year period of FY 2024-25, Windlas Biotech stock price delivered strong appreciation driven by CDMO client additions and injectable capacity commissioning before entering consolidation in the second half. The three-year CAGR (Compound Annual Growth Rate) from FY 2022-23 to FY 2024-25 has reflected positive compounding from post-IPO recovery. Over the five-year CAGR spanning FY 2020-21 to FY 2024-25, Windlas Biotech share price history has demonstrated moderate long-term appreciation from IPO base. Windlas Biotech investor sentiment has remained broadly constructive with institutional interest growing. Windlas Biotech volatility has been moderate, consistent with its mid-cap pharmaceutical CDMO profile.

Windlas Biotech Investor Relevance And Role In Portfolio

Windlas Biotech investment thesis has remained grounded in its top-five position among India’s domestic pharmaceutical formulations CDMO operators, with a growing injectable capacity, diversified client base across sixteen of India’s top twenty pharma companies, and an expanding export vertical. Windlas Biotech share price has served as a proxy for India’s domestic pharma outsourcing growth story. Windlas Biotech P/E ratio (Price-to-Earnings ratio) has remained at a reasonable discount to larger diversified pharmaceutical peers through FY 2024-25. Windlas Biotech EPS (Earnings Per Share) has demonstrated consistent improvement through FY 2024-25 driven by operating leverage and CDMO volume growth. Windlas Biotech long-term outlook has been reinforced by rising chronic disease prevalence, growing domestic pharma outsourcing adoption, and export market expansion. Windlas Biotech fundamentals have remained sound with a growing revenue base and improving profitability. Windlas Biotech live price has attracted both institutional and growth-oriented retail investors through FY 2024-25. A final dividend was declared for FY 2024-25.

Windlas Biotech Sectoral Relevance And Peer Positioning

Windlas Biotech peer comparison within India’s listed pharmaceutical CDMO and contract manufacturing sector includes Divi’s Laboratories Limited, Laurus Labs Limited, Suven Pharmaceuticals Limited, and Syngene International Limited. Windlas Biotech is viewed as a cleaner proxy for India’s domestic formulations CDMO segment than API (Active Pharmaceutical Ingredient)-oriented peers such as Divi’s Laboratories and Laurus Labs, given its exclusive focus on finished dosage form CDMO for the domestic Indian market alongside growing export contribution. Windlas Biotech market cap has placed it in the small-cap to mid-cap bracket, attracting institutional coverage from domestic and overseas funds tracking India’s pharma outsourcing theme. Windlas Biotech SWOT analysis highlights strengths including WHO-GMP and US-FDA compliant manufacturing, long-term client relationships with top Indian pharma companies, injectable diversification, and growing export revenues, while high client concentration in the CDMO vertical and competitive intensity from emerging CDMO operators remain key considerations.

Windlas Biotech Summary

Windlas Biotech share price has continued to serve as a sentiment indicator for India’s domestic pharmaceutical CDMO outsourcing sector through FY 2024-25. Windlas Biotech business model has demonstrated structural resilience through its multi-vertical CDMO, Trade Generics, and Exports architecture backed by compliant, high-capacity manufacturing. Windlas Biotech stock price has remained anchored to CDMO volume growth, injectable capacity ramp-up, and export vertical momentum.